Valuation are "very high" in the pharmaceutical sector, Roche CEO Severin Schwan told CNBC on Thursday after the company posted a rise in sales.» Read More
June 22- The U.S. Food and Drug Administration on Monday approved Medicines Co's blood clot preventer Cangrelor, which has faced multiple setbacks since it first entered late-stage studies close to a decade back. Medicines Co has funneled about $200 million into developing Cangrelor over the past decade, which included two unsuccessful trials and a pivotal...
The "Halftime Report" traders give their top trades for the second half of the day.
Goldman Sachs is recommending fund manager clients buy the stocks that their peers are neglecting in order to beat the S&P 500 this year.
CHICAGO, June 2- Drugmakers including Bristol-Myers Squibb Co and Merck& Co are testing which patients will most benefit from new cancer treatments based on a protein found in their tumors, but that guide, known as a biomarker, may be too unreliable, researchers and health experts said. Competitors Roche Holding, AstraZeneca and Pfizer also have similar drugs in...
RBC Capital Markets' Michael Yee said the selloff of Puma Biotech is in an overreaction and that the stock will represents an opportunity in the long run.
U.S. stocks closed higher on June's first trading day as investors found some encouragement from mixed second-quarter economic reports.
The "Halftime Report" traders give their trades for the second half.
U.S. stock index futures tracked Asian and European equities higher on Monday, after indifferent data from China raised expectations of further stimulus.
The stock-moving news flow started early out of the American Society of Clinical Oncology meeting in Chicago.
Bristol-Myers Squibb's battering after a disappointing drug trial serves as a buying opportunity, "Fast Money" traders said.
*Humana hits record on takeover interest. *Altera rises on report of Intel interest. May 29- U.S. stocks closed lower on Friday as data showed the economy contracted in the first quarter but indexes still posted gains for the month.
Chicago May 29- Bristol-Myers Squibb Co's drug, Opdivo, improved survival in a trial of patients with the most common form of lung cancer, but it did not work in patients who tested negative for a specific protein in their tumors, leading to a nearly 7 percent sell-off in the company's shares on Friday. The Bristol drug was approved by U.S. regulators in December to...
Incyte stands to benefit from unveiling data on its cancer treatments at a conference in the coming days, a biotech analyst said.
It's that time again. With researchers set to convene at the American Society of Clinical Oncology meeting, here are the stocks to watch.
A study sheds light on why the new medicines seem to work for some cancers and not others, NYT reports.
Chicago May 29- Bristol-Myers Squibb Co's drug, Opdivo, improved survival for patients with the most common form of lung cancer, nearly doubling survival for those with high levels of a specific protein in their tumors compared with chemotherapy, according to clinical trial results presented on Friday. The Bristol drug was approved by U.S. regulators in...
BRISTOL-MYERS SQUIBB'S OPDIVO EXTENDS SURVIVAL IN ADVANCED NON-SQUAMOUS NON-SMALL CELL LUNG CANCER-STUDY.
New data provided to CNBC from eVestment shows the most popular stocks held by institutional funds.
The "Fast Money" traders give their final trades of the day.
May 22- EU Medicines Agency:. *EU Medicines Agency recommendations for May 2015. *Recommends approval of cholesterol drug Repatha from Amgen Inc.